Trials / Completed
CompletedNCT01238055
Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
Randomized Phase II Trial of Sunitinib and Docetaxel in Advanced Gastric Cancer Patients Who Had Prior Chemotherapy With Fluoropyrimidine and Platinum
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Sunitinib and Docetaxel is effective in the treatment of advanced gastric cancer patients who had prior chemotherapy with fluoropyrimidine and platinum.
Detailed description
This is a randomized phase II trial of Sunitinib and Docetaxel in advanced gastric cancer patients who had prior chemotherapy with Fluoropyrimidine and Platinum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel + Sunitinib | Docetaxel 60 mg/m2 iv, every 3 weeks Sunitinib 37.5 mg qd daily, every 3 weeks |
| DRUG | Docetaxel only | Docetaxel 60 mg/m2 iv |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2012-04-01
- Completion
- 2012-10-01
- First posted
- 2010-11-10
- Last updated
- 2013-04-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01238055. Inclusion in this directory is not an endorsement.